Onyx Pharms Amgen Drug Patent Portfolio

Onyx Pharms Amgen owns 1 orange book drug protected by 12 US patents Given below is the list of Onyx Pharms Amgen's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9493582 Alkylated cyclodextrin compositions and processes for preparing and using the same 27 Feb, 2033
Active
US9511109 Combination therapy with peptide epoxyketones 21 Oct, 2029
Active
USRE47954 Combination therapy with peptide epoxyketones 21 Oct, 2029
Active
US7737112 Composition for enzyme inhibition 07 Dec, 2027
Active
US7417042 Compounds for enzyme inhibition 20 Jul, 2026
Active
US7232818 Compounds for enzyme inhibition 14 Apr, 2025
Active
US7491704 Compounds for enzyme inhibition 14 Apr, 2025
Active
US8129346 Compounds for enzyme inhibition 14 Apr, 2025
Active
US8207125 Compounds for enzyme inhibition 14 Apr, 2025
Active
US8207126 Compounds for enzyme inhibition 14 Apr, 2025
Active
US8207127 Compounds for enzyme inhibition 14 Apr, 2025
Active
US8207297 Compounds for enzyme inhibition 14 Apr, 2025
Active


Given below is the list of recent legal activities going on the following drug patents of Onyx Pharms Amgen.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 30 Apr, 2024 US9493582
Payment of Maintenance Fee, 12th Year, Large Entity 21 Nov, 2023 US8207297 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 21 Nov, 2023 US8207125 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 21 Nov, 2023 US8207127 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 21 Nov, 2023 US8207126 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 22 Aug, 2023 US8129346 (Litigated)
Correspondence Address Change 04 Dec, 2022 US9493582
Payment of Maintenance Fee, 12th Year, Large Entity 01 Dec, 2021 US7737112 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 06 Aug, 2020 US7491704 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 30 Apr, 2020 US9493582
Payment of Maintenance Fee, 12th Year, Large Entity 13 Feb, 2020 US7417042 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 13 Dec, 2019 US8207125 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 13 Dec, 2019 US8207297 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 13 Dec, 2019 US8207127 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 13 Dec, 2019 US8207126 (Litigated)


Onyx Pharms Amgen's Family Patents

Onyx Pharms Amgen drugs have patent protection in a total of 41 countries. It's US patent count contributes only to 26.7% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Onyx Pharms Amgen Drug List

Given below is the complete list of Onyx Pharms Amgen's drugs and the patents protecting them.


1. Kyprolis

Kyprolis is protected by 12 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9493582 Alkylated cyclodextrin compositions and processes for preparing and using the same 27 Feb, 2033
(8 years from now)
Active
US9511109 Combination therapy with peptide epoxyketones 21 Oct, 2029
(5 years from now)
Active
USRE47954 Combination therapy with peptide epoxyketones 21 Oct, 2029
(5 years from now)
Active
US7737112 Composition for enzyme inhibition 07 Dec, 2027
(3 years from now)
Active
US7417042 Compounds for enzyme inhibition 20 Jul, 2026
(1 year, 9 months from now)
Active
US7232818 Compounds for enzyme inhibition 14 Apr, 2025
(6 months from now)
Active
US7491704 Compounds for enzyme inhibition 14 Apr, 2025
(6 months from now)
Active
US8129346 Compounds for enzyme inhibition 14 Apr, 2025
(6 months from now)
Active
US8207125 Compounds for enzyme inhibition 14 Apr, 2025
(6 months from now)
Active
US8207126 Compounds for enzyme inhibition 14 Apr, 2025
(6 months from now)
Active
US8207127 Compounds for enzyme inhibition 14 Apr, 2025
(6 months from now)
Active
US8207297 Compounds for enzyme inhibition 14 Apr, 2025
(6 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kyprolis's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List